Search

Your search keyword '"Ng LF"' showing total 139 results

Search Constraints

Start Over You searched for: Author "Ng LF" Remove constraint Author: "Ng LF"
139 results on '"Ng LF"'

Search Results

3. Conference Reports

4. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.

5. A role for dextran in pseudomyxoma peritonei?

6. Development of Proniosome Gel Formulation for CHIKV Infection.

7. Mechanical Characterization, Water Absorption, and Thickness Swelling of Lightweight Pineapple Leaf/Ramie Fabric-Reinforced Polypropylene Hybrid Composites.

8. Crosstalk between CD64 + MHCII + macrophages and CD4 + T cells drives joint pathology during chikungunya.

9. Acquired immunity against SARS-CoV-2 infection and vaccination.

10. Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine.

11. LipidClock: A Lipid-Based Predictor of Biological Age.

12. Organ-specific immune response in lethal SARS-CoV-2 infection by deep spatial phenotyping.

13. Glutathione catabolism by Enterobacteriaceae species to hydrogen sulphide adversely affects the viability of host systems in the presence of 5'fluorodeoxyuridine.

14. A small-molecule Psora-4 acts as a caloric restriction mimetic to promote longevity in C. elegans.

15. Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection.

16. Malaria abrogates O'nyong-nyong virus pathologies by restricting virus infection in nonimmune cells.

17. Optogenetic approaches for understanding homeostatic and degenerative processes in Drosophila.

19. Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study.

20. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation.

21. Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.

22. Inhibition of mTOR decreases insoluble proteins burden by reducing translation in C. elegans.

23. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19.

24. Systematic analysis of disease-specific immunological signatures in patients with febrile illness from Saudi Arabia.

25. Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.

26. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.

27. Lifespan and healthspan benefits of exogenous H 2 S in C. elegans are independent from effects downstream of eat-2 mutation.

28. Type I interferon shapes the quantity and quality of the anti-Zika virus antibody response.

29. Erratum: Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients.

30. Immunological observations and transcriptomic analysis of trimester-specific full-term placentas from three Zika virus-infected women.

31. WNT Signaling in Disease.

32. Inhibition of amyloid-induced toxicity by ergothioneine in a transgenic Caenorhabditis elegans model.

33. Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients.

34. Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate.

35. Measurement of Respiration Rate in Live Caenorhabditis elegans .

36. Mitochondrial DNA Damage Does Not Determine C. elegans Lifespan.

37. Viperin controls chikungunya virus-specific pathogenic T cell IFNγ Th1 stimulation in mice.

38. Lipid profiling of C. elegans strains administered pro-longevity drugs and drug combinations.

39. Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling.

40. Clonal expansion of mitochondrial DNA deletions is a private mechanism of aging in long-lived animals.

41. Co-infection with Chikungunya virus alters trafficking of pathogenic CD8 + T cells into the brain and prevents Plasmodium -induced neuropathology.

42. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections.

43. Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.

44. Increased Serum Hyaluronic Acid and Heparan Sulfate in Dengue Fever: Association with Plasma Leakage and Disease Severity.

45. Identification of a previously undetected metabolic defect in the Complex II Caenorhabditis elegans mev-1 mutant strain using respiratory control analysis.

46. Zika Virus Infects Human Fetal Brain Microglia and Induces Inflammation.

47. Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.

48. Fingolimod treatment abrogates chikungunya virus-induced arthralgia.

49. Severity of Plasma Leakage Is Associated With High Levels of Interferon γ-Inducible Protein 10, Hepatocyte Growth Factor, Matrix Metalloproteinase 2 (MMP-2), and MMP-9 During Dengue Virus Infection.

50. The Role of Mitochondrial Non-Enzymatic Protein Acylation in Ageing.

Catalog

Books, media, physical & digital resources